Multicentric Castleman Disease (MCD) Overview

Save information for later
Sign Up

Learn About Multicentric Castleman Disease (MCD)

View Main Condition: Castleman Disease

What is the definition of Multicentric Castleman Disease (MCD)?
Multicentric Castleman Disease (MCD) is a rare disease that affects the lymph nodes and related tissues. It is a form of Castleman disease that is "systemic" and involves multiple regions of lymph nodes (as opposed to unicentric Castleman disease, which involves a single lymph node or single region of lymph nodes). The signs and symptoms of MCD are often nonspecific, and are mild in some people but serious in others. Symptoms may include enlarged lymph nodes in multiple regions, fever, weight loss, nausea, rash, and/or an enlarged large liver and spleen. The disease is diagnosed based on the symptoms present, laboratory test results, imaging studies, and results of a biopsy of the lymph nodes which shows specific features when studied under the microscope. In some cases, MCD is caused by human herpesvirus-8 (HHV-8) and is referred to as HHV-8-associated MCD. In other cases, the cause is not known and it is referred to as HHV-8 negative MCD, or idiopathic MCD (iMCD).
What are the alternative names for Multicentric Castleman Disease (MCD)?
  • Multicentric Castleman Disease
  • Idiopathic multicentric Castleman's disease
  • MCD
  • Multicentric giant lymph node hyperplasia
  • Multicentric plasma cell variant of Castleman's disease
  • PMCD
  • Plasmablastic multicentric Castleman disease
Who are the top Multicentric Castleman Disease (MCD) Local Doctors?
Sudipto Mukherjee
Elite in Multicentric Castleman Disease (MCD)
Dr. Sudipto Mukherjee
Hematology | Oncology
Elite in Multicentric Castleman Disease (MCD)
Dr. Sudipto Mukherjee
Hematology | Oncology

Cleveland Clinic Main Campus

10201 Carnegie Avenue, 
Cleveland, OH 
866-223-8100
Languages Spoken:
English, Bengali, Hindi
See accepted insurances
Offers Telehealth

Sudipto Mukherjee is a Hematologist and an Oncologist in Cleveland, Ohio. Dr. Mukherjee is rated as an Elite provider by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Multicentric Castleman Disease (MCD), Castleman Disease, Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), and Bone Marrow Aspiration.

Elite in Multicentric Castleman Disease (MCD)
Eric Oksenhendler
Elite in Multicentric Castleman Disease (MCD)
Eric Oksenhendler
Paris, FR 

Eric Oksenhendler practices in Paris, France. Mr. Oksenhendler is rated as an Elite expert by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Castleman Disease, Multicentric Castleman Disease (MCD), Lymphoid Hyperplasia, Unicentric Castleman Disease (UCD), and Splenectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Multicentric Castleman Disease (MCD)
Lionel Galicier
Elite in Multicentric Castleman Disease (MCD)
Lionel Galicier
Université Paris Est, 
Creteil, FR 

Lionel Galicier practices in Creteil, France. Mr. Galicier is rated as an Elite expert by MediFind in the treatment of Multicentric Castleman Disease (MCD). His top areas of expertise are Castleman Disease, Multicentric Castleman Disease (MCD), Thrombocytopenia, Splenectomy, and Bone Marrow Aspiration.

View All Doctors
What are the latest Multicentric Castleman Disease (MCD) Clinical Trials?
A Phase II, Single-Arm Open-Label Multi-Center Study of Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
A Phase II, Single-Arm Open-Label Multi-Center Study of Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
Enrollment Status: Recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Phase: Phase 2

Summary: The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten better from taking siltuximab or tocilizumab, or who cannot take those medications.

Match to trials
Find the right clinical trials for you in under a minute
Get started
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
Enrollment Status: Recruiting
Publish Date: September 15, 2025
Intervention Type: Drug
Study Phase: Phase 2

Background: Kaposi sarcoma herpesvirus (KSHV)-associated inflammatory cytokine syndrome (KICS) and KSHV-multicentric Castleman disease (MCD) occur in people living with HIV. These diseases cause severe inflammation that can be fatal if not treated.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are some Advocacy Organizations?
castleman-disease

The Castleman Disease Collaborative Network (CDCN) is a global initiative dedicated to accelerating research and treatment for Castleman disease and revolutionizing biomedical research.